MedPath

A Study to Evaluate the Efficacy and Safety of AD-223

Phase 3
Recruiting
Conditions
Hypertension,Essential
Interventions
Drug: AD-223A
Drug: AD-223C
Drug: AD-223B
Drug: AD-223B Placebo
Drug: AD-223A Placebo
Drug: AD-223C Placebo
Registration Number
NCT06052748
Lead Sponsor
Addpharma Inc.
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of AD-223

Detailed Description

Condition or disease : hypertension

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
486
Inclusion Criteria
  • Signed informed consent
  • Other inclusions applied
Read More
Exclusion Criteria
  • Orthostatic hypotension with symptom
  • Other exclusions applied
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Test groupAD-223AAD-223A+AD-223B+AD-223C Placebo
Test groupAD-223BAD-223A+AD-223B+AD-223C Placebo
Test groupAD-223C PlaceboAD-223A+AD-223B+AD-223C Placebo
Control group 1AD-223AAD-223A+AD-223B Placebo+AD-223C Placebo
Control group 1AD-223B PlaceboAD-223A+AD-223B Placebo+AD-223C Placebo
Control group 1AD-223C PlaceboAD-223A+AD-223B Placebo+AD-223C Placebo
Control group 2AD-223BAD-223A Placebo+AD-223B+AD-223C Placebo
Control group 2AD-223A PlaceboAD-223A Placebo+AD-223B+AD-223C Placebo
Control group 2AD-223C PlaceboAD-223A Placebo+AD-223B+AD-223C Placebo
Control group 3AD-223CAD-223A Placebo+AD-223B Placebo+AD-223C
Control group 3AD-223A PlaceboAD-223A Placebo+AD-223B Placebo+AD-223C
Control group 3AD-223B PlaceboAD-223A Placebo+AD-223B Placebo+AD-223C
Primary Outcome Measures
NameTimeMethod
Change rate of MSSBPBaseline, Week 8

Change from baseline in mean sitting systolic blood pressure

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hanyang University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath